Product description
Lovastatin API CAS 75330-75-5 is a hexahydronaphthalene ester isolated from Aspergillus terrestris culture. It is an inactive lactone that becomes active only after hydrolysis. In the liver, it exhibits a strong competitive inhibitory effect on HMG-CoA reductase. HMG-CoA reductase is the rate-limiting enzyme in de novo cholesterol synthesis. Inhibition of this enzyme blocks the conversion of HMG-CoA to methylvalerate, significantly reducing cholesterol synthesis, leading to increased expression of hepatic LDL receptors and enhanced clearance of plasma LDL-C. Reduced cholesterol synthesis also reduces hepatic ApoB100 synthesis, thereby decreasing VLDL synthesis.
The structures of statins are very similar among naturally occurring statins. They share the same hydroxylhexahydronaphthalene polyketide moiety, with different side chains attached at C8 (R1) and C6 (R2) positions. Lovastatin has a methylbutyryl side chain at R1 and a 6-α-methyl side chain at R2; mevastatin lacks a 6-methyl group. Natural statins exist as lactones and require enzymatic hydrolysis to reach their acidic form in vivo to become active. While fully synthetic statins differ structurally from natural statins, they still possess an open-ring lactone moiety, sharing the common structure of all statins that competitively inhibits HMG-CoA reductase.
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
COA
| Tests | Specifications | Results |
| Appearance | White to off-white crystalline powder | Complies |
| Solubility | Freely soluble in water and ethanol,slightly soluble in chloroform |
Complies |
| Identification Tests | HPLC Retention Time RT matches reference(±2%) | 12.45min |
| FTIR Spectrum Matches USPreference spectrum | Complies | |
| UV-Vis (λmax)246nm(in methanol) | Complies | |
| Assay | 98.0-102.0% | 99.8% |
| Related Substances | Impurity A:≤0.5% | 0.4% |
| Impurity B:≤0.5% | 0.3% | |
| Total Impuritie:≤2.0% | 0.9% | |
| Water Content | ≤1.0% | 0.5% |
| Heavy Metals | Pb≤5 ppm,Cd≤3ppm,As≤2ppm | <1 ppm(each) |
| Microbial Limits | Total Plate Count<1000cfu/g | <100cfu/g |
| Yeast &Moulds<100cfug | <10cfuv/g | |
| E.Coli Negative | Negative | |
| Salmonella Negative | Negative | |
| Conclusion | Conform with enterprise specification | |
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
Density: 1.1 ± 0.1 g/cm³
Boiling point: 559.2 ± 50.0 °C at 760 mmHg
Melting point: 175 °C
Molecular formula: C24H36O5
Molecular weight: 404.540
Flash point: 185.3 ± 23.6 °C
Precise mass: 404.256287
PSA: 72.83000
LogP: 4.07
Pharmacological Value of Lovastatin API CAS 75330-75-5
1. Lipid-Regulating Effect: Lovastatin blocks the synthesis of endogenous cholesterol by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing intracellular cholesterol levels. This, in turn, increases the number of LDL receptors on the cell surface, accelerating the uptake and degradation of LDL particles in the bloodstream, thus reducing total cholesterol, very low-density lipoprotein (VLDL), LDL, and triglycerides in plasma. Since the conversion of HMG-CoA to mevalonate is an early step in the cholesterol biosynthesis pathway, the use of Lovastatin does not cause the accumulation of potentially toxic cholesterol substances. Furthermore, HMG-CoA can be quickly metabolized back into acetyl-CoA to participate in other biosynthetic pathways in the body. This inhibitory effect is incomplete and reversible, exhibiting a dose-response relationship. At therapeutic doses, it does not affect the amount of cholesterol required for normal cell membrane function. Therefore, Lovastatin has a significant lipid-lowering effect with relatively few side effects. In summary, Lovastatin exerts its effects primarily through the following mechanisms: ① competitive inhibition of HMG-CoA reductase activity, reducing endogenous cholesterol synthesis; ② increasing LDL receptor expression in hepatocytes, enhancing receptor-mediated plasma LDL clearance; ③ inhibiting smooth muscle cell migration and proliferation; and ④ reducing hepatic lipoprotein assembly and secretion.
2. Non-lipid-regulating effects: In addition to its significant lipid-lowering effects, Lovastatin also significantly improves endothelial cell function and promotes the production of nitric oxide synthase (eNOS), thereby increasing NO synthesis and release. This plays a crucial role in maintaining normal pulmonary vascular tone and reversing hypoxia-induced pulmonary vasoconstriction and vascular remodeling. Furthermore, Lovastatin possesses anti-inflammatory and anti-proliferative effects, inhibiting the proliferation of renal mesangial cells and the secretion of extracellular matrix, thus alleviating glomerular sclerosis.
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
why choose us
Our Factory
Package
Shipping Methods
|
Transportation Time |
Shipping method |
Cargo weight requirements |
Advantage |
|
3-7 days |
DHL,Germany DHL,Germany DPD, |
Suitable for under 50kg. |
We have warehouses in Germany and California, USA, and customers in Europe and America can enjoy sending goods directly from these two places. |
|
7-15 days |
By Air |
Suitable for more than 50kg. |
|
|
15-60 days |
By Sea |
Suitable for more than 500kg. |
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
FAQ
01. What diseases is Lovastatin API CAS 75330-75-5 primarily used to treat?
Lovastatin belongs to the statin class of lipid-lowering products, with two main indications: Treatment of hypercholesterolemia and mixed hyperlipidemia, especially suitable for patients whose primary symptom is elevated low-density lipoprotein cholesterol (LDL-C); and prevention and treatment of coronary heart disease, reducing the incidence and mortality of myocardial infarction in patients with coronary heart disease, while also slowing the progression of atherosclerotic plaques.
02. What should I do if I experience muscle soreness or weakness while using Lovastatin API CAS 75330-75-5?
Muscle system reactions are a relatively common adverse reaction to Lovastatin. There are two approaches: If it is only mild muscle pain and weakness without other discomfort, you can observe it first and inform your doctor immediately so they can assess whether creatine kinase (CK) levels need to be monitored. If you experience severe muscle pain, severe weakness, or dark brown urine, you should seek medical attention immediately. This may be a rare but serious condition called rhabdomyolysis, and delaying treatment may damage kidney function.
03. Where can I buy Lovastatin API CAS 75330-75-5?
Hot Tags: lovastatin api cas 75330-75-5, China, suppliers, manufacturers, factory, customized, wholesale, buy, price, bulk, pure, producer, discount, for sale, in stock, free sample, raw powder, raw material, made in China